Security Snapshot

Rani Therapeutics Holdings, Inc. - Class A Common Stock, $0.0001 par value per share (RANI) Institutional Ownership

CUSIP: 753018100

13F Institutional Holders and Ownership History from Q3 2021 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

67

Shares (Excl. Options)

45.66MFull value: 45,663,300 · shares · 30 Jun 2026

Price

$0.76

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Class A Common Stock, $0.0001 par value per share
Symbol
RANI on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
45,663,300
Latest holder snapshot 5 signals
Total 13F value
$34,720,523
Portfolio coverage rank
0%
Share change
+6,630,476
Value change
+$5,076,057
Number of holders
67
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
116,468,828
SEC-reported price per share
$0.79
Insider filing price
$0.79
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • RANI - Rani Therapeutics Holdings, Inc. - Class A Common Stock, $0.0001 par value per share is tracked under CUSIP 753018100.
  • 67 institutions reported positions in Q2 2026.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 73 to 67 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $31.41MFull value: $31,411,019 · USD · 31 Mar 2026
    to
    $34.72MFull value: $34,720,523 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 67 institutions filings for Q2 2026.

Open SEC evidence

Security key

753018100

13F reference period

Q2 2026

13F holders

67

13D/G owners

10

CIK / CUSIP context first

Open Q2 2026 holders RANI full holder history Rani Therapeutics Holdings, Inc. SEC filings Rani Therapeutics Holdings, Inc. company facts Rani Therapeutics Holdings, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
RANI
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
InCube Labs, L.L.C. 22% $13,541,357 27,093,552 MIR A IMRAN 23 Oct 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $8,763,115 +$1,252,432 11,530,414 +17% RA Capital Management, L.P. 30 Jun 2026
Samsara BioCapital, L.P. 9.9% 0% $10,417,124 +$1,325,245 11,322,961 +15% Srinivas Akkaraju 26 May 2026
Invus Global Management, LLC 10% $4,910,990 9,825,911 Raymond Debbane 16 Oct 2025
AWM Investment Company, Inc. 9.9% $14,520,561 9,745,343 AWM Investment Company, Inc. 31 Dec 2025
ARMISTICE CAPITAL, LLC 9.9% $4,131,600 6,260,000 Armistice Capital, LLC 30 Jun 2025
VANGUARD GROUP INC 5.2% $6,897,647 5,109,368 The Vanguard Group 31 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC 4.5% $3,840,175 5,052,862 Vanguard Capital Management 30 Jun 2026
South Cone Investments Limited Partnership 4.9% $1,189,121 2,379,194 South Cone Investments Limited Partnership 20 Oct 2025
Orca Capital AG 4.3% -56% $972,105 -$1,265,416 1,891,623 -57% Orca Capital AG 22 Jul 2025
As of 30 Jun 2026, 67 institutional investors reported holding
45.66MFull value: 45,663,300 · shares · 30 Jun 2026
shares of Rani Therapeutics Holdings, Inc. - Class A Common Stock, $0.0001 par value per share (RANI). This represents 39% of the company’s total
116.47MFull value: 116,468,828 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
39%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
SAMSARA BIOCAPITAL, LLC 8.9% 10,369,159 +22% 0.65% $7,884,709
RA CAPITAL MANAGEMENT, L.P. 7.3% 8,500,000 0% 0.06% $6,463,400
AWM Investment Company, Inc. 6.4% 7,500,000 +15% 0.49% $5,703,000
VANGUARD CAPITAL MANAGEMENT LLC 3.9% 4,562,985 -1.3% 0% $3,467,869
Longaeva Partners L.P. 2% 2,329,459 0% 0.05% $1,771,321
Polar Asset Management Partners Inc. 2% 2,318,542 0.03% $1,763,019
Siren, L.L.C. 1.7% 2,000,000 0% 0.03% $1,520,800
HEIGHTS CAPITAL MANAGEMENT, INC 0.8% 934,580 0.16% $710,655
GEODE CAPITAL MANAGEMENT, LLC 0.76% 890,618 -1.4% 0% $677,575
CITADEL ADVISORS LLC 0.55% 641,995 0% $488,173
MARSHALL WACE, LLP 0.5% 586,265 0% $445,561
Nan Fung Group Holdings Ltd 0.42% 493,584 0% 0.29% $375,321
JANE STREET GROUP, LLC 0.42% 485,899 +193% 0% $369,478
VANGUARD FIDUCIARY TRUST CO 0.39% 458,126 +0.68% 0% $348,176
RENAISSANCE TECHNOLOGIES LLC 0.37% 430,737 0% $327,532
STATE STREET CORP 0.32% 373,142 0% 0% $283,737
BlackRock, Inc. 0.29% 342,113 -39% 0% $260,142
UNITED SERVICES AUTOMOBILE ASSOCIATION 0.26% 302,743 0% 0.02% $230,206
UBS Group AG 0.26% 297,270 +31% 0% $225,926
KESTRA PRIVATE WEALTH SERVICES, LLC 0.24% 282,340 +6.5% 0% $214,691
GSA CAPITAL PARTNERS LLP 0.21% 249,716 +157% 0.01% $190,000
NORTHERN TRUST CORP 0.15% 170,471 0% 0% $129,626
CWA Asset Management Group, LLC 0.13% 150,000 0% 0% $114,060
Cygnus Capital Advisors, LLC 0.1% 116,432 +0.68% 0.06% $89,000
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.1% 114,500 0% 0% $87,066

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
21
Headline period
Q2 2026
Rows shown
1-21 of 21
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 602,135 $476,485 -$6,570 $0.79 12
2026 Q2 45,663,300 $34,720,523 +$5,076,057 $0.76 67
2026 Q1 42,744,667 $31,411,019 -$1,642,213 $0.73 73
2025 Q4 44,799,019 $60,478,537 +$47,505,485 $1.35 61
2025 Q3 4,033,213 $2,015,817 -$1,258,453 $0.50 36
2025 Q2 6,458,632 $3,319,783 +$1,060,111 $0.51 38
2025 Q1 3,609,389 $4,577,211 -$332,797 $1.26 38
2024 Q4 3,819,967 $5,233,595 -$4,950,047 $1.37 42
2024 Q3 5,911,071 $12,767,865 +$5,999,502 $2.16 31
2024 Q2 3,108,475 $11,809,884 -$1,252,441 $3.80 33
2024 Q1 3,453,784 $10,741,251 +$509,498 $3.11 35
2023 Q4 3,290,303 $10,923,496 -$819,783 $3.32 33
2023 Q3 3,207,291 $6,961,738 -$151,646 $2.18 32
2023 Q2 3,227,286 $13,256,941 +$994,179 $4.12 34
2023 Q1 2,999,366 $15,475,095 +$204,634 $5.16 35
2022 Q4 2,885,407 $17,024,416 -$1,472,942 $5.90 32
2022 Q3 3,174,344 $30,405,447 +$3,581,808 $9.58 30
2022 Q2 2,824,819 $29,094,000 +$2,769,956 $10.33 27
2022 Q1 2,556,816 $34,515,000 +$17,568,047 $13.50 23
2021 Q4 1,240,919 $20,288,000 +$544,189 $16.35 21
2021 Q3 1,097,698 $19,562,000 +$19,562,000 $17.82 14
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .